RepliCel Life Sciences, Inc.
RepliCel is a regenerative medicine company focused on aesthetics and orthopedics. They develop autologous cell therapies to treat conditions like aging or sun-damaged skin, hair loss, and tendon degeneration. Their next-generation dermal injection technology aims to revolutionize aesthetic treatment outcomes, and they operate through a network of strategic partners and contract research organizations worldwide.
Industries
Nr. of Employees
small (1-50)
RepliCel Life Sciences, Inc.
Suite 900, 570 Granville Street, Vancouver, BC V6C 3P1
Patents
Products
Cell therapy for pattern baldness (RCH-01)
An autologous cell therapy derived from hair-follicle cell populations intended to restore hair growth in androgenetic alopecia; advanced through safety and dose-finding studies and in pivotal efficacy testing.
Cell therapy for aging and sun-damaged skin (RCS-01)
An autologous cell therapy intended to rejuvenate aging or UV-damaged skin by restoring collagen-based extracellular matrix under the dermis.
Cell therapy for tendon degeneration (RCT-01)
An autologous cell therapy derived from skin/hair-follicle cells developed to treat chronic tendinopathy and tendon degeneration in various anatomic sites.
Next-generation precision dermal injection device
An electronic injector designed to provide controlled intradermal and subcutaneous delivery with precise control over depth, dose and pressure, capable of injecting highly viscous products and including features to reduce patient discomfort.
Cell therapy for pattern baldness (RCH-01)
An autologous cell therapy derived from hair-follicle cell populations intended to restore hair growth in androgenetic alopecia; advanced through safety and dose-finding studies and in pivotal efficacy testing.
Cell therapy for aging and sun-damaged skin (RCS-01)
An autologous cell therapy intended to rejuvenate aging or UV-damaged skin by restoring collagen-based extracellular matrix under the dermis.
Cell therapy for tendon degeneration (RCT-01)
An autologous cell therapy derived from skin/hair-follicle cells developed to treat chronic tendinopathy and tendon degeneration in various anatomic sites.
Next-generation precision dermal injection device
An electronic injector designed to provide controlled intradermal and subcutaneous delivery with precise control over depth, dose and pressure, capable of injecting highly viscous products and including features to reduce patient discomfort.
Services
Structuring and executing exclusive regional licenses and commercialization agreements for cell therapy products and injection devices.
Coordination with CROs and CDMOs for clinical research, process development, and technology transfer to support manufacturing scale-up.
Design and oversight of clinical studies including randomized, placebo-controlled phase I trials and progression to pivotal studies across multiple jurisdictions.
Transfer of proprietary processes and device technologies to contract manufacturers and support for partner-led commercialization efforts.
Structuring and executing exclusive regional licenses and commercialization agreements for cell therapy products and injection devices.
Coordination with CROs and CDMOs for clinical research, process development, and technology transfer to support manufacturing scale-up.
Design and oversight of clinical studies including randomized, placebo-controlled phase I trials and progression to pivotal studies across multiple jurisdictions.
Transfer of proprietary processes and device technologies to contract manufacturers and support for partner-led commercialization efforts.
Expertise Areas
- Autologous cell therapy development
- Primary cell isolation and expansion
- Clinical trial management (Phase I to pivotal)
- Dermal and subcutaneous injection systems
Key Technologies
- Autologous cell therapy from hair follicles
- Primary cell culture and expansion
- Precision-controlled dermal/subcutaneous injection systems
- Injection parameter control (depth, dose, pressure)
News & Updates
RepliCel presented and conducted one-on-one partnering meetings in January 2018.
RepliCel presented and conducted one-on-one partnering meetings in January 2016.
RepliCel announced its annual general and special meeting for September 22, 2023.
The company completed its name change from 'Replicel Life Sciences Inc.' to '0913693 B.C. Ltd.' in March 2025.
An article discussing the potential of stem cell research to regenerate hair follicles resistant to hair loss, and RepliCel's involvement in hair regeneration technology.
An interview with David Hall, CEO of RepliCel, discussing the company's focus on regenerative medicine and its strategic partnerships.
RepliCel presented and conducted one-on-one partnering meetings in January 2018.
RepliCel presented and conducted one-on-one partnering meetings in January 2016.
RepliCel announced its annual general and special meeting for September 22, 2023.
The company completed its name change from 'Replicel Life Sciences Inc.' to '0913693 B.C. Ltd.' in March 2025.
An article discussing the potential of stem cell research to regenerate hair follicles resistant to hair loss, and RepliCel's involvement in hair regeneration technology.
An interview with David Hall, CEO of RepliCel, discussing the company's focus on regenerative medicine and its strategic partnerships.